NO20032181D0 - Anvendelse av CCI-779 som et antineoplastisk middel - Google Patents

Anvendelse av CCI-779 som et antineoplastisk middel

Info

Publication number: NO20032181D0
Authority: NO; Norway
Prior art keywords: cci; antineoplastic agent; antineoplastic; agent
Prior art date: 2000-11-15

Application number

NO20032181A

Other languages

English (en)

Norwegian (no)

Other versions

NO20032181L (no

Inventor

Gary Dukart

Jr James Joseph Gibbons

Lisa Anne Speicher

Philip Frost

Carolyn Mary Discafani-Marro

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-15

Filing date

2003-05-14

Publication date

2003-05-14

2003-05-14 Application filed by Wyeth Corp filed Critical Wyeth Corp

2003-05-14 Publication of NO20032181L publication Critical patent/NO20032181L/no

2003-05-14 Publication of NO20032181D0 publication Critical patent/NO20032181D0/no

Links

CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 title 1
229940034982 antineoplastic agent Drugs 0.000 title 1
239000002246 antineoplastic agent Substances 0.000 title 1
229960000235 temsirolimus Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20032181A 2000-11-15 2003-05-14 Anvendelse av CCI-779 som et antineoplastisk middel NO20032181D0 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US24907700P	2000-11-15	2000-11-15
PCT/US2001/047324 WO2002040000A2 (fr)	2000-11-15	2001-11-13	Utilisation du cci-779 en tant qu'agent antineoplasique

Publications (2)

Publication Number	Publication Date
NO20032181L NO20032181L (no)	2003-05-14
NO20032181D0 true NO20032181D0 (no)	2003-05-14

Family

ID=22941961

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20032181A NO20032181D0 (no)	2000-11-15	2003-05-14	Anvendelse av CCI-779 som et antineoplastisk middel

Country Status (27)

Country	Link
US (3)	US20020091137A1 (fr)
EP (1)	EP1335725B1 (fr)
JP (4)	JP4472251B2 (fr)
KR (1)	KR100827942B1 (fr)
CN (2)	CN102058588A (fr)
AR (1)	AR031341A1 (fr)
AT (1)	ATE393629T1 (fr)
AU (2)	AU2731302A (fr)
BR (1)	BR0115323A (fr)
CA (1)	CA2429020C (fr)
CY (1)	CY1108109T1 (fr)
DE (1)	DE60133831T2 (fr)
DK (1)	DK1335725T3 (fr)
EA (1)	EA007096B1 (fr)
ES (1)	ES2305134T3 (fr)
HU (1)	HUP0400521A3 (fr)
IL (2)	IL155871A0 (fr)
MX (1)	MXPA03004192A (fr)
NO (1)	NO20032181D0 (fr)
NZ (1)	NZ539668A (fr)
PL (1)	PL207061B1 (fr)
PT (1)	PT1335725E (fr)
SG (1)	SG148031A1 (fr)
SI (1)	SI1335725T1 (fr)
TW (1)	TWI286074B (fr)
WO (1)	WO2002040000A2 (fr)
ZA (1)	ZA200304603B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5362718A (en)	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
TWI286074B (en) *	2000-11-15	2007-09-01	Wyeth Corp	Pharmaceutical composition containing CCI-779 as an antineoplastic agent
EP1363627A2 (fr)	2001-02-19	2003-11-26	Novartis AG	Traitement des cancers
TWI296196B (en) *	2001-04-06	2008-05-01	Wyeth Corp	Antineoplastic combinations
ZA200603888B (en) *	2001-06-01	2007-05-30	Wyeth Corp	Antineoplastic combinations
WO2002098416A2 (fr) *	2001-06-01	2002-12-12	Wyeth	Combinaisons antineoplasiques
EP1478648B1 (fr) *	2002-02-01	2014-04-30	ARIAD Pharmaceuticals, Inc.	Composes contenant du phosphore et utilisations associees
AU2003280437A1 (en) *	2002-06-27	2004-01-19	Microport Medical (Shanghai) Co., Ltd.	Drug eluting stent
TWI307277B (en) *	2002-07-30	2009-03-11	Wyeth Corp	Parenteral formulations
US20040077677A1 (en) *	2002-09-17	2004-04-22	Wyeth	Oral formulations
AU2003298689A1 (en)	2002-11-21	2004-06-18	Wyeth	Methods for diagnosing rcc and other solid tumors
US7643943B2 (en)	2003-02-11	2010-01-05	Wyeth Llc	Methods for monitoring drug activities in vivo
US20050287532A9 (en) *	2003-02-11	2005-12-29	Burczynski Michael E	Methods for monitoring drug activities in vivo
EP1592811A2 (fr) *	2003-02-11	2005-11-09	Wyeth	Procedes pour controler in vivo des activites de medicaments
UA83484C2 (uk) *	2003-03-05	2008-07-25	Уайт	Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
WO2004093854A2 (fr) *	2003-04-22	2004-11-04	Wyeth	Combinaisons antitumorales
US20060194211A1 (en) *	2003-04-29	2006-08-31	Burczynski Michael E	Methods for prognosis and treatment of solid tumors
RU2345772C2 (ru) *	2003-07-25	2009-02-10	Уайт	Лиофилизированные композиции cci-779
AR046194A1 (es) *	2003-11-04	2005-11-30	Mayo Foundation	Metodo de tratamiento del linfoma de celulas del manto
BRPI0418373A (pt) *	2004-01-08	2007-05-22	Wyeth Corp	composição farmacêutica, unidade de dosagem de cci-779 oral, método de fornecimento de cci-779 a um paciente, e, uso de cci-779 micronizado
AR047988A1 (es) *	2004-03-11	2006-03-15	Wyeth Corp	Combinaciones antineoplásicas de cci-779 y rituximab
BRPI0606839B8 (pt)	2005-02-03	2021-12-14	Massachusetts Gen Hospital	Uso de uma composição farmacêutica compreendendo um inibidor irreversível de receptor de fator de crescimento epidérmico (egfr)
RU2007127499A (ru) *	2005-02-15	2009-03-27	Вайет (Us)	Таблетированные композиции, содержащие cci-779 в биодоступной при пероральном введении форме
RU2451524C2 (ru) *	2005-11-04	2012-05-27	Вайет	Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272
ES2481671T3 (es) *	2005-11-21	2014-07-31	Novartis Ag	Inhibidores de mTOR en el tratamiento de tumores endocrinos
WO2007075621A1 (fr) *	2005-12-20	2007-07-05	Wyeth	Maitrise de la stabilite de la forme pharmaceutique de cci-779 par l'elimination optimale des impuretes de la substance medicamenteuse
DE102006011507A1 (de) *	2006-03-14	2007-09-20	Lts Lohmann Therapie-Systeme Ag	Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
TW200901989A (en) *	2007-04-10	2009-01-16	Wyeth Corp	Anti-tumor activity of CCI-779 in papillary renal cell cancer
US20090076060A1 (en) *	2007-09-17	2009-03-19	Protia, Llc	Deuterium-enriched temsirolimus
EP3142297B1 (fr) *	2007-10-03	2019-02-06	Genesis Technical Systems, Corp.	Anneaux dynamiques asymétriques
US8022216B2 (en)	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
AU2013205002B2 (en) *	2008-03-21	2016-09-15	The University Of Chicago	Treatment with opioid antagonists and mTOR inhibitors
US8685995B2 (en)	2008-03-21	2014-04-01	The University Of Chicago	Treatment with opioid antagonists and mTOR inhibitors
SG191676A1 (en)	2008-06-17	2013-07-31	Wyeth Llc	Antineoplastic combinations containing hki-272 and vinorelbine
CN109464445A (zh)	2008-08-04	2019-03-15	惠氏有限责任公司	4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
SG174382A1 (en)	2009-04-06	2011-11-28	Wyeth Llc	Treatment regimen utilizing neratinib for breast cancer
US8716307B2 (en) *	2009-05-13	2014-05-06	The Trustees Of The University Of Pennsylvania	Combination antineoplastic therapy
JP2013527223A (ja) *	2010-06-02	2013-06-27	フレゼニウス・カビ・オンコロジー・リミテッド	ラパマイシンエステルの安定な医薬組成物
US9745941B2 (en) *	2014-04-29	2017-08-29	Ford Global Technologies, Llc	Tunable starter resistor
US10300026B2 (en) *	2015-08-24	2019-05-28	Shanxi Yabao Health Products Co., Ltd.	Use of dihydroxyacetone in preparation of anti-cancer medicaments
CN111110676A (zh) *	2020-03-07	2020-05-08	天津医科大学总医院	阿帕替尼及联合cci-779在制备肺癌药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en)	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US3993749A (en)	1974-04-12	1976-11-23	Ayerst Mckenna And Harrison Ltd.	Rapamycin and process of preparation
US4885171A (en)	1978-11-03	1989-12-05	American Home Products Corporation	Use of rapamycin in treatment of certain tumors
US5206018A (en)	1978-11-03	1993-04-27	Ayerst, Mckenna & Harrison, Inc.	Use of rapamycin in treatment of tumors
BE877700A (fr) *	1978-11-03	1980-01-14	Ayerst Mckenna & Harrison	Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US4401653A (en)	1981-03-09	1983-08-30	Ayerst, Mckenna & Harrison Inc.	Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en)	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5078999A (en)	1991-02-22	1992-01-07	American Home Products Corporation	Method of treating systemic lupus erythematosus
US5080899A (en)	1991-02-22	1992-01-14	American Home Products Corporation	Method of treating pulmonary inflammation
US5321009A (en)	1991-04-03	1994-06-14	American Home Products Corporation	Method of treating diabetes
ATE135583T1 (de)	1991-06-18	1996-04-15	American Home Prod	Verwendung von rapamycin zur behandlung von t- zellen lymphom/leukämie bei erwachsenen
IL102414A (en)	1991-07-25	1996-08-04	Univ Louisville Res Found	Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5286730A (en)	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory disease
US5286731A (en)	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory bowel disease
US5516781A (en)	1992-01-09	1996-05-14	American Home Products Corporation	Method of treating restenosis with rapamycin
US5288711A (en)	1992-04-28	1994-02-22	American Home Products Corporation	Method of treating hyperproliferative vascular disease
ZA935112B (en)	1992-07-17	1994-02-08	Smithkline Beecham Corp	Rapamycin derivatives
US5362718A (en) *	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
US5561138A (en)	1994-12-13	1996-10-01	American Home Products Corporation	Method of treating anemia
US5496832A (en)	1995-03-09	1996-03-05	American Home Products Corporation	Method of treating cardiac inflammatory disease
WO2002013802A2 (fr)	2000-08-11	2002-02-21	Wyeth	Procede de traitement d'un carcinome a recepteur d'oestrogene
TWI286074B (en) *	2000-11-15	2007-09-01	Wyeth Corp	Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en)	2001-04-06	2008-05-01	Wyeth Corp	Antineoplastic combinations
TWI233359B (en)	2001-04-06	2005-06-01	Wyeth Corp	Pharmaceutical composition for treating neoplasm
UA77200C2 (en)	2001-08-07	2006-11-15	Wyeth Corp	Antineoplastic combination of cci-779 and bkb-569

2001
- 2001-11-05 TW TW090127415A patent/TWI286074B/zh not_active IP Right Cessation
- 2001-11-13 JP JP2002542375A patent/JP4472251B2/ja not_active Expired - Lifetime
- 2001-11-13 KR KR1020037006542A patent/KR100827942B1/ko not_active Expired - Lifetime
- 2001-11-13 CN CN2010101653331A patent/CN102058588A/zh active Pending
- 2001-11-13 SG SG200505237-8A patent/SG148031A1/en unknown
- 2001-11-13 DK DK01996175T patent/DK1335725T3/da active
- 2001-11-13 PT PT01996175T patent/PT1335725E/pt unknown
- 2001-11-13 US US10/010,584 patent/US20020091137A1/en not_active Abandoned
- 2001-11-13 EP EP01996175A patent/EP1335725B1/fr not_active Expired - Lifetime
- 2001-11-13 SI SI200130829T patent/SI1335725T1/sl unknown
- 2001-11-13 PL PL362740A patent/PL207061B1/pl unknown
- 2001-11-13 DE DE60133831T patent/DE60133831T2/de not_active Expired - Lifetime
- 2001-11-13 WO PCT/US2001/047324 patent/WO2002040000A2/fr not_active Ceased
- 2001-11-13 EA EA200300566A patent/EA007096B1/ru not_active IP Right Cessation
- 2001-11-13 AT AT01996175T patent/ATE393629T1/de not_active IP Right Cessation
- 2001-11-13 IL IL15587101A patent/IL155871A0/xx unknown
- 2001-11-13 BR BR0115323-4A patent/BR0115323A/pt not_active Application Discontinuation
- 2001-11-13 HU HU0400521A patent/HUP0400521A3/hu unknown
- 2001-11-13 CN CNA018189261A patent/CN1678312A/zh active Pending
- 2001-11-13 ES ES01996175T patent/ES2305134T3/es not_active Expired - Lifetime
- 2001-11-13 AU AU2731302A patent/AU2731302A/xx active Pending
- 2001-11-13 MX MXPA03004192A patent/MXPA03004192A/es active IP Right Grant
- 2001-11-13 NZ NZ539668A patent/NZ539668A/en unknown
- 2001-11-13 CA CA002429020A patent/CA2429020C/fr not_active Expired - Lifetime
- 2001-11-14 AR ARP010105310A patent/AR031341A1/es unknown
2003
- 2003-02-26 US US10/374,644 patent/US7189735B2/en not_active Expired - Lifetime
- 2003-05-12 IL IL155871A patent/IL155871A/en active IP Right Grant
- 2003-05-14 NO NO20032181A patent/NO20032181D0/no not_active Application Discontinuation
- 2003-06-12 ZA ZA200304603A patent/ZA200304603B/en unknown
2007
- 2007-02-01 US US11/701,109 patent/US7781446B2/en not_active Expired - Fee Related
- 2007-03-27 AU AU2007201324A patent/AU2007201324B2/en not_active Expired
2008
- 2008-06-02 CY CY20081100573T patent/CY1108109T1/el unknown
2009
- 2009-09-18 JP JP2009216883A patent/JP2010018620A/ja active Pending
2014
- 2014-01-15 JP JP2014005231A patent/JP2014088430A/ja not_active Withdrawn
2015
- 2015-12-10 JP JP2015241449A patent/JP2016094444A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
HUP0400521A3 (en)	2007-05-29
CA2429020A1 (fr)	2002-05-23
KR100827942B1 (ko)	2008-05-13
KR20040029309A (ko)	2004-04-06
JP2010018620A (ja)	2010-01-28
IL155871A (en)	2012-03-29
DK1335725T3 (da)	2008-06-30
US20020091137A1 (en)	2002-07-11
SI1335725T1 (sl)	2008-08-31
CA2429020C (fr)	2009-05-26
TWI286074B (en)	2007-09-01
PL207061B1 (pl)	2010-10-29
AU2731302A (en)	2002-05-27
EP1335725B1 (fr)	2008-04-30
DE60133831T2 (de)	2009-05-20
US7781446B2 (en)	2010-08-24
MXPA03004192A (es)	2003-09-22
AR031341A1 (es)	2003-09-17
HK1058008A1 (en)	2004-04-30
JP2004517065A (ja)	2004-06-10
CN1678312A (zh)	2005-10-05
AU2007201324B2 (en)	2010-11-18
EP1335725A2 (fr)	2003-08-20
BR0115323A (pt)	2004-02-17
NZ539668A (en)	2007-06-29
PT1335725E (pt)	2008-06-19
EA007096B1 (ru)	2006-06-30
WO2002040000A3 (fr)	2002-09-06
WO2002040000A2 (fr)	2002-05-23
HUP0400521A2 (hu)	2004-06-28
US7189735B2 (en)	2007-03-13
AU2007201324A1 (en)	2007-04-19
US20030153593A1 (en)	2003-08-14
PL362740A1 (en)	2004-11-02
DE60133831D1 (de)	2008-06-12
CN102058588A (zh)	2011-05-18
JP2016094444A (ja)	2016-05-26
ES2305134T3 (es)	2008-11-01
JP2014088430A (ja)	2014-05-15
US20070142425A1 (en)	2007-06-21
SG148031A1 (en)	2008-12-31
ATE393629T1 (de)	2008-05-15
NO20032181L (no)	2003-05-14
ZA200304603B (en)	2004-09-13
JP4472251B2 (ja)	2010-06-02
EA200300566A1 (ru)	2003-10-30
IL155871A0 (en)	2003-12-23
CY1108109T1 (el)	2014-02-12

Publication	Publication Date	Title
NO20032181D0 (no)	2003-05-14	Anvendelse av CCI-779 som et antineoplastisk middel
NL300343I1 (nl)	2008-06-02	6-alfa, 9-alfa-difluor-17-alfa-(2-furanylcarboxyl)oxy-11-beta-hydroxy-16-alfa-methyl-3-oxo-androst-1, 4-dieen-17-carbothionzuur-s-fluormethylester alseen ontstekingremmend middel
NO20015855D0 (no)	2001-11-30	Ny anvendelse av forbindelser som antibakterielle midler
NO20030929D0 (no)	2003-02-27	Guanidinobenzamider som MC4-R agonister
NO20026037L (no)	2003-02-06	Sötvareprodukt som inneholder aktive bestanddeler
AR028567A1 (es)	2003-05-14	Nuevos derivados de fenil-propargileter
DK1250047T3 (da)	2005-05-30	Herbicidt middel
NO20030138D0 (no)	2003-01-10	Lipidrikt plakkinnkapslende middel
PT1399127E (pt)	2005-07-29	Formulacoes de olopatadina para administracao topica
NO20035193L (no)	2003-11-21	Nye pyrrolderivater som farmas degree ytiske midler
AR028596A1 (es)	2003-05-14	Nuevos derivados de fenilglicina
NO20042112L (no)	2004-07-09	Anvendelse av glycosider av mono- og diacylglycerol som anti-inflammatoriske midler.
NO20012636D0 (no)	2001-05-29	Kontrollert frigivelsesformulering som omfatter GNRH-II
NO20041316L (no)	2004-03-30	Tiofen- og tiazoisulfonamider som antineoplastiske midler
NO20054790D0 (no)	2005-10-18	Anvendelse av B7-113 som et immunoregulatorisk middel
DK1073416T3 (da)	2009-03-09	Anvendelse af NO som anti-inflammatorisk middel
NO20043100L (no)	2004-08-26	Indolylalkylaminderivater som 5-hydroksytryptamin-6-ligander
DK1355900T3 (da)	2006-09-11	Heterocyclylalkylindol- eller -azaindolforbindelser som 5-hydroxytryptamin-6-ligander
NO20021959D0 (no)	2002-04-25	Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
DK1144431T3 (da)	2006-05-08	16-Hydroxyestratriener som selektivt aktive estrogener
NO20043084L (no)	2004-07-16	3-fenyl-2-arylalkyltiopropionsyre derivater som selektive agnoister av PPAR-ALPHA
PT1268482E (pt)	2004-01-30	Piranoindois para o tratamento de glaucoma
DE60220799D1 (de)	2007-08-02	Hypoglykämisches mittel
AR028398A1 (es)	2003-05-07	Ciclipostinas, procedimiento para su preparacion, y utilizacion de las mismas
NO20033981D0 (no)	2003-09-09	Imidazolidinderivater, deres fremstilling og deres anvendelse som antiinflammatorisk middel

Legal Events

Date	Code	Title	Description
2011-05-30	FC2A	Withdrawal, rejection or dismissal of laid open patent application